It seems to me, one rather large difficulty with medical cannabis prescription is a lack of method for meeting the western prescriptive model. In Western studies of cannabinoids for therapeutic use, study after study continues to focus on a single analyte, where it is clear to those of us in the industry that benefits arise from a broad spectrum of cooperative analytes in varying chemotypical ratios. How do we convince larger research institutions to pursue this approach, despite its complexities? How do we, as analytical cannabis laboratories with big data (e.g. multi-spectral, microbial, genes, cannabinoid, terpene, alkanes, etc) on 50,000+ examined samples contribute to clinical science without bumping into the federal fear that some large educational institutions seem to not be able to shake?
Confidence_Analytics10 karma
It seems to me, one rather large difficulty with medical cannabis prescription is a lack of method for meeting the western prescriptive model. In Western studies of cannabinoids for therapeutic use, study after study continues to focus on a single analyte, where it is clear to those of us in the industry that benefits arise from a broad spectrum of cooperative analytes in varying chemotypical ratios. How do we convince larger research institutions to pursue this approach, despite its complexities? How do we, as analytical cannabis laboratories with big data (e.g. multi-spectral, microbial, genes, cannabinoid, terpene, alkanes, etc) on 50,000+ examined samples contribute to clinical science without bumping into the federal fear that some large educational institutions seem to not be able to shake?
View HistoryShare Link